HHMI
BMRN icon

Howard Hughes Medical Institute’s BioMarin Pharmaceuticals BMRN Stock Holding History

Howard Hughes Medical Institute’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,460
Closed -$133K – 45
2017
Q2 		$133K Sell
1,460
-820
-36% -$74.6K 0.02% 133
2017
Q1 		$200K Buy
2,280
+1,451
+175% +$129K 0.04% 114
2016
Q4 		$69K Buy
+829
New +$71.3K 0.02% 138

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Howard Hughes Medical Institute's BMRN Position: Q3 2017 in Review

Howard Hughes Medical Institute sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 1,460 shares — an estimated $133K sold.

Howard Hughes Medical Institute first reported a position in BMRN in Q4 2016 and held it in 3 quarters. The position peaked at $200K in Q1 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • Howard Hughes Medical Institute reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 1,460 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $133K.
  • Howard Hughes Medical Institute first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Howard Hughes Medical Institute's BioMarin Pharmaceuticals position peaked at $200K in Q1 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Howard Hughes Medical Institute's 13F filing for Q3 2017, filed 2 Nov 2017.